Nexalin Technology said it has regained compliance with Nasdaq's minimum bid price requirement after the closing bid price of its common stock stayed above $1.00 per share for 21 consecutive trading days, from August 31 through September 29, 2026, following its previously announced reverse stock split. The confirmation, dated September 30, 2026, follows a September 25, 2026 decision by the Nasdaq Hearings Panel granting the company's request for continued listing. Under the Panel's decision, Nexalin must still demonstrate compliance with the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) on or before January 4, 2027. Chief Executive Officer Mark White said the company's primary focus remains on business momentum, citing a recently announced distribution agreement covering Brazil and six additional South American markets and the advancement of its U.S. clinical programs, including the pivotal HALO Clarity clinical trial in insomnia. Nexalin said its continued listing remains subject to the Panel's terms, including prompt notification of any significant events during the exception period, and that there can be no assurance it will meet the stockholders' equity requirement in time.
Nexalin Technology Inc.Nexalin regained Nasdaq minimum bid price compliance and won a Panel decision granting continued listing, easing delisting risk.
